These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 201573)

  • 21. Enhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis.
    Hutt LM; Huang YT; Dascomb HE; Pagano JS
    J Immunol; 1975 Jul; 115(1):243-8. PubMed ID: 168255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphonoacetic acid: inhibition of transformation of human cord blood lymphocytes by Epstein-Barr virus.
    Manor D; Margalith M
    Cancer Biochem Biophys; 1979; 3(4):157-62. PubMed ID: 233303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus.
    Thorley-Lawson DA; Strominger JL
    Virology; 1978 May; 86(2):423-31. PubMed ID: 208257
    [No Abstract]   [Full Text] [Related]  

  • 24. Simultaneous presence of EBNA-positive and colony-forming cells in peripheral blood of patients with infectious mononucleosis.
    Katsuki T; Hinuma Y; Saito T; Yamamoto J; Hirashima Y; Sudoh H; Deguchi M; Motokawa M
    Int J Cancer; 1979 Jun; 23(6):746-50. PubMed ID: 223990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis.
    Hewetson JF; Rocchi G; Henle W; Henle G
    J Infect Dis; 1973 Sep; 128(3):283-9. PubMed ID: 4353929
    [No Abstract]   [Full Text] [Related]  

  • 26. Cell mediated immunity during infectious mononucleosis to Epstein-Barr virus associated antigens.
    Periman P; Levine PH; Ablashi DV; Royston I
    Int J Cancer; 1977 Oct; 20(4):506-11. PubMed ID: 199544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.
    Datta AK; Hood RE
    Virology; 1981 Oct; 114(1):52-9. PubMed ID: 6269292
    [No Abstract]   [Full Text] [Related]  

  • 28. Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients.
    Cao P; Zhang M; Wang W; Dai Y; Sai B; Sun J; Wang L; Wang F; Li G; Xiang J
    BMC Infect Dis; 2017 May; 17(1):323. PubMed ID: 28468603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus genome in infectious mononucleosis.
    Pagano JS; Huang CH; Huang YT
    Nature; 1976 Oct; 263(5580):787-9. PubMed ID: 186715
    [No Abstract]   [Full Text] [Related]  

  • 30. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis.
    Enssle KH; Fleischer B
    Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colonies of EBNA-positive cells in soft agar from peripheral leukocytes of infectious mononucleosis patients.
    Hinuma Y; Katsuki T
    Int J Cancer; 1978 Apr; 21(4):426-31. PubMed ID: 78908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.
    Svedmyr E; Jondal M
    Proc Natl Acad Sci U S A; 1975 Apr; 72(4):1622-6. PubMed ID: 165518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis.
    Miller G; Niederman JC; Andrews LL
    N Engl J Med; 1973 Feb; 288(5):229-32. PubMed ID: 4345064
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.
    Strang G; Rickinson AB
    Immunology; 1987 Dec; 62(4):647-54. PubMed ID: 2828228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [EB virus and infectious mononucleosis].
    Hinuma Y
    Nihon Rinsho; 1977 Sep; 35(9):2729-32. PubMed ID: 200773
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen.
    Sairenji T; Nguyen QV; Woda B; Humphreys RE
    J Immunol; 1987 Apr; 138(8):2645-52. PubMed ID: 2435803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sites of Epstein-Barr virus replication in acute and chronic active Epstein-Barr virus infections.
    Kikuta H; Osato T; Matsumoto S
    Intervirology; 1989; 30(6):346-50. PubMed ID: 2559902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.
    Miller G; Robinson J; Heston L; Lipman M
    Proc Natl Acad Sci U S A; 1974 Oct; 71(10):4006-10. PubMed ID: 4372601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of cell lines derived from human leukocytes transformed by different strains of Epstein-Barr virus.
    Katsuki T; Hinuma Y
    Int J Cancer; 1975 Feb; 15(2):203-10. PubMed ID: 165154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
    Klein G; Dombos L; Gothoskar B
    Int J Cancer; 1972 Jul; 10(1):44-57. PubMed ID: 4122458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.